Transcriptome Analysis of Individual Stromal Cell Populations Identifies Stroma-Tumor Crosstalk in Mouse Lung Cancer Model  by Choi, Hyejin et al.
ResourceTranscriptome Analysis of Individual Stromal Cell
Populations Identifies Stroma-Tumor Crosstalk in
Mouse Lung Cancer ModelGraphical AbstractHighlightsd Tumor microenvironment heterogeneity is analyzed in
KrasG12D/+;p53/ lung cancer
d RNA-seq identifies differentially expressed genes in stromal
and epithelial cells
d A computational model is developed, identifying paracrine/
autocrine crosstalk
d Computationally predicted crosstalk pathway is
experimentally validatedChoi et al., 2015, Cell Reports 10, 1187–1201
February 24, 2015 ª2015 The Authors
http://dx.doi.org/10.1016/j.celrep.2015.01.040Authors
Hyejin Choi, Jianting Sheng, ...,
Stephen T.C. Wong, Vivek Mittal
Correspondence
stwong@houstonmethodist.org
(S.T.C.W.),
vim2010@med.cornell.edu (V.M.)
In Brief
The tumor-stroma crosstalk network in
lung cancer is poorly understood. Choi
et al. analyze cellular heterogeneity of
stromal cells in KrasG12D/+;p53/ lung
cancer and identify the reprogrammed
states of individual myeloid cells and
tumor cells by RNA-seq analysis. The
authors develop a computational model
that identifies global paracrine/autocrine
crosstalk networks.Accession NumbersGSE59831
Cell Reports
ResourceTranscriptome Analysis of Individual Stromal Cell
Populations Identifies Stroma-Tumor Crosstalk
in Mouse Lung Cancer Model
Hyejin Choi,1,2,3,4,11 Jianting Sheng,8,11 Dingcheng Gao,1,2,3 Fuhai Li,8 Anna Durrans,1,2,3 Seongho Ryu,1,3,10
Sharrell B. Lee,1,2,3 Navneet Narula,6 Shahin Rafii,7 Olivier Elemento,5 Nasser K. Altorki,1,3 Stephen T.C. Wong,6,8,9,*
and Vivek Mittal1,2,3,*
1Department of Cardiothoracic Surgery
2Department of Cell and Developmental Biology
3Neuberger Berman Lung Cancer Center
4Weill Cornell Graduate School of Medical Sciences
5Institute for Computational Biomedicine, Department of Physiology and Biophysics
6Department of Pathology
7Ansary Stem Cell Institute and Department of Genetic Medicine
Weill Cornell Medical College of Cornell University, 1300 York Avenue, 525 East 68th Street, New York, NY 10065, USA
8Department of Systems Medicine and Bioengineering, Houston Methodist Research Institute, 6670 Bertner Avenue, Houston, TX 77030, USA
9Methodist Cancer Center, Houston Methodist Hospital, 6650 Fannin Street, Houston, TX 77030, USA
10Present address: Soonchunhyang Institute of Medi-bio Science (SIMS), Soonchunhyang University, Asan 336-745, Korea
11Co-first author
*Correspondence: stwong@houstonmethodist.org (S.T.C.W.), vim2010@med.cornell.edu (V.M.)
http://dx.doi.org/10.1016/j.celrep.2015.01.040
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
Emerging studies have begun to demonstrate that re-
programmed stromal cells play pivotal roles in tumor
growth, metastasis, and resistance to therapy. How-
ever, the contribution of stromal cells to non-small-
cell lung cancer (NSCLC) has remained underex-
plored. We used an orthotopic model of Kras-driven
NSCLC to systematically dissect the contribution of
specific hematopoietic stromal cells in lung cancer.
RNA deep-sequencing analysis of individually sorted
myeloid lineage and tumor epithelial cells revealed
cell-type-specific differentially regulated genes, in-
dicative of activated stroma. We developed a com-
putational model for crosstalk signaling discovery
based on ligand-receptor interactions and down-
stream signaling networks and identified known and
novel tumor-stroma paracrine and tumor autocrine
crosstalk-signaling pathways in NSCLC. We provide
cellular and molecular insights into components of
the lung cancer microenvironment that contribute
to carcinogenesis. This study has the potential for
development of therapeutic strategies that target
tumor-stroma interactionsandmaycomplement con-
ventional anti-cancer treatments.
INTRODUCTION
Lung cancer is a major health problem with an estimated
220,000 new cases per year in the United States. It is the leadingCell Rcause of cancer-related mortality and accounts for more deaths
in men and women than the three next most common cancers
combined: prostate/breast; colorectal; and pancreatic, which
together attribute to 26%–28% of all cancer deaths (Siegel
et al., 2014). Targeted therapies benefit only 15%–20% of non-
small-cell lung cancer (NSCLC) patients harboring drug-sensi-
tive mutations. Even in these patients, acquired resistance is a
major impediment to a durable therapeutic response (Choi
et al., 2010; Pao et al., 2005). Moreover, over 40% of NSCLC pa-
tients do not comprise identifiable driver mutations and thus lack
actionable or druggable targets. Therefore, standard cytotoxic
chemotherapy regimens remain the only therapeutic options
for most NSCLC patients. However, these treatments eventually
fail, resulting in acquired resistance and aggressive metastatic
relapse within 5 years of diagnosis. Thus, molecular analysis of
NSCLC is necessary to identify novel molecular targets that
impact disease prognosis and the design of novel targeted ther-
apies. In this context, more-recent studies have begun to focus
on the tumor microenvironment (TME) as an unexplored target
for drug discovery (Blumenschein, 2012).
TME is heterogeneous and includes reprogrammed or acti-
vated immune cells, cancer-associated fibroblasts (CAFs), and
endothelial cells (Hanahan and Coussens, 2012). The concerted
interactions between genetically altered cancer cells and intratu-
moral stromal cells regulate hallmarks of cancer, including angio-
genesis, inflammation, immune suppression, invasion, epithelial-
to-mesenchymal transition (EMT), and metastasis (Hanahan and
Coussens, 2012). Notably, targeting intratumoral macrophages,
in combination with standard cytotoxic chemotherapy, was
effective in the treatment of breast cancer (DeNardo et al.,
2011; Shree et al., 2011), and a similar approach was utilized in
the treatment of glioblastoma (Pyonteck et al., 2013).eports 10, 1187–1201, February 24, 2015 ª2015 The Authors 1187
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Figure 1. BM-Derived Cells Are Increased in Tumor-Bearing Lungs
(A) HKP1 orthotopic tumor-bearing lungs stained with H&E, scale bar 100 mm (top), and with fluorescence-conjugated antibodies against CD45 and Epcam
(bottom), scale bar 50 mm.
(B) Flow cytometry scatterplots showing various subpopulation of cells in the lung fromWT and HKP1-tumor-bearing mice. The parental cell population for each
analysis is indicated on the top of each plot. Total number of lung cells was normalized with counting beads, and the same corresponding area of total lung cells
from WT and tumor-bearing lungs is presented.
(legend continued on next page)
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Although little is known about the precise role of stromal cells
in NSCLC, a few studies have shown that the stromal elements
confer prognostic value and may also contribute to resistance
to targeted therapies in lung cancer. For example, in patients
with stage I lung adenocarcinoma or squamous cell carcinoma,
the presence of CAFs is considered a poor prognostic indicator,
typically associated with nodal metastases and a higher risk of
recurrence (Ito et al., 2012). Similarly, elevated recruitment of
myeloid lineages including neutrophils and macrophages has
been shown to confer prognostic value in NSCLC patients (Bel-
locq et al., 1998; Welsh et al., 2005). Furthermore, intratumoral
stromal cells exhibit differential expression of genes compared
with their non-tumor-associated counterparts. For example,
intratumoral macrophages express increased cathepsin K,
COX-2, MMP-9, PDGF-B, uPA, VEGFA, and HGF (Wang et al.,
2011); neutrophils express neutrophil elastase (Houghton et al.,
2010); and myeloid cells express PPARg (Li et al., 2011), sug-
gesting that, in NSCLC, altered activation/reprogramming of
stromal cells by the tumor epithelial cells contribute to tumor
progression.
To characterize the stromal cell heterogeneity in lung cancer,
we used an orthotopic model of NSCLC in syngeneic immuno-
competent mice, which develops adenocarcinoma with histo-
pathological similarities to human NSCLC. This model has
enabled us to identify, quantify, and sort individual stromal and
epithelial populations. We analyzed the transcriptomes of spe-
cific stromal and epithelial compartments sorted directly from
tumor tissues and normal lungs and identified potential tumor-
stroma paracrine and tumor autocrine crosstalk-signaling
pathways using the newly developed computational crosstalk-
signaling discovery model, Cell Cell Communication Explorer
(CCCExplorer).
RESULTS
Establishment of an Orthotopic Model of Kras-Driven
NSCLC
In the genetically engineered Kras-driven NSCLC mouse model,
the KrasLSL-G12D/+;p53fl/fl (KP) transgenic mouse develops lung
adenocarcinoma following intratracheal instillation of lentiviral/
adenoviral Cre recombinase (DuPage et al., 2009). Following
Cre recombinase-mediated excision of the Kras oncogene
stop element and the p53 gene, detectable adenocarcinomas
are observed by 15–20 weeks. However, in this model, in addi-
tion to epithelial cells, stromal cells also have the potential to
be infected by Viral-Cre. To determine the impact of virus
infection on non-epithelial cells in the lungs, we generated the
LSL- tdTomato; KP mouse. Administration of Viral-Cre showed
that approximately 40% of tdTomato+ cells were CD45+ he-
matopoietic cells, suggesting that Viral-Cre infection has the
ability to induce Kras activation and loss of p53 in the CD45+
cells (Figure S1A). Therefore, considering that CD45+ stromal
cells are our main cell population of interest, and to avoid any(C) Quantification of CD45+ cells in lungs from WT and HKP1-tumor-bearing mic
(D) Quantification of CD11b+ cells in lungs from WT and HKP1-tumor-bearing m
(E) Quantification of subsets of CD11b+ and CD3+ cells in lungs from WT and H
Data are shown as mean ± SEM. *p < 0.05 by Mann-Whitney U test.
Cell Rpotential alteration in the stroma mediated by Viral-Cre admin-
istration, we generated an orthotopic KP model in syngeneic
immunocompetent mice. The orthotopic model maintains an
intact host microenvironment during lung cancer progression.
A lung cancer cell line for developing the orthotopicmodel was
derived from lung adenocarcinoma that was generated by intra-
tracheal administration of Cre/luciferase-expressing lentivirus
into a KP transgenic mouse (Figure S1B). The cells (HKP1)
were delivered to the lungs via the tail vein, and lung tumor pro-
gression was monitored by in vivo bioluminescence imaging
(BLI) (Figure S1C). HKP1-derived tumors were detectable in all
animals as early as day 20, by both BLI and gross morphological
analysis of lungs (Figure S1C). Notably, HKP1-derived adeno-
carcinomaswere histologically comparable with the adenocarci-
nomas in KP transgenic mice (Figure S1D). Furthermore, the
HKP1-derived tumors showed mixed histological subtypes
including acinar and micropapillary adenocarcinomas, resem-
bling phenotypes commonly observed in human adenocarci-
noma (Solis et al., 2012; Figures S1E and S1F). The HKP1-
derived orthotopic model was used to evaluate the contribution
of the TME in tumor progression, by analyzing cellular composi-
tion and transcriptome of specific stromal and epithelial com-
partments that were sorted directly from the tumor parenchyma.
Lung Cancer Microenvironment Consists of Diverse
Immune Cells
Bone-marrow-derived CD45+ hematopoietic cells contribute
significantly to the TME in many cancer types (Hanahan and
Coussens, 2012; Joyce and Pollard, 2009). Therefore, we inves-
tigated CD45+ hematopoietic cells in NSCLC by immunofluores-
cencemicroscopy and flow cytometry. An increase in the CD45+
population was observed in the lungs of HKP1-tumor-bearing
mice (Figures 1A–1C), consistent with observations in sponta-
neous KP mice (Figure S2A) and in human lung adenocarcinoma
(Figure S2D) by immunostaining. Flow cytometry analysis
showed an increase in CD45+ cells in HKP1-tumor-bearing
lungs compared to wild-type (WT) lungs (>2-fold more cells per
lung; Figures 1B and 1C).
The heterogeneous CD45+ hematopoietic population includes
cells of the myeloid lineage, subsets of T lymphocytes, and B
cells (Ruffell et al., 2012). We analyzed these cellular subsets us-
ing specific cell-surface markers by flow cytometry (Figures
S2E). CD11b+ cells representing the myeloid lineages were
significantly (p < 0.05) increased in the TME (>7-fold; Figure 1D),
whereas the CD4+ and CD8+ lymphocyte populations were
not significantly elevated (Figure 1E). We further explored the
CD11b+ myeloid lineages, as these cells have been implicated
in promoting tumor growth by stimulating angiogenesis, medi-
ating immune suppression, and promoting metastasis (Joyce
and Pollard, 2009). Of the myeloid lineages, the CD11b+
Ly6G+ neutrophils were significantly (p < 0.05) increased in the
TME (Figures 1B and 1E). We also identified CD11b+CD11c+
tumor-associated macrophages as significantly increased ine by flow cytometry (n = 3).
ice by flow cytometry (n = 3).
KP1-tumor-bearing mice by flow cytometry (n = 3).
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the lung TME (Figures 1B and 1E). Consistent with published
studies, the CD11b+ intratumoral macrophages lacked expres-
sion of Ly6G and Ly6C (Gr1 markers; Pyonteck et al., 2013)
and expressed CD11c (Franklin et al., 2014; Figure 1B). Ki67
staining showed that a majority of CD11b+ cells (99.7%) in
lung tumors were Ki67 negative (Figures S2F and S2G), suggest-
ing that recruitment from the bone marrow compartments
had resulted in elevated levels of myeloid lineage cells in
the TME.
We next evaluated CD45+ stromal cell populations in sponta-
neous adenocarcinomas in KP transgenic mice. Consistent with
the HKP1 tumors, KP tumors showed increased bone-marrow-
derived CD45+ cells (Figures S2A and S2B) and an overall similar
trend in the infiltration of various hematopoietic subsets (Fig-
ure S2C). Subtle differences were noted as well; for example,
CD11b+Ly6G+ neutrophils were significantly (p < 0.05) in-
creased in HKP1 tumors, but not in KP tumors (Figures 1E and
S2C). This may reflect differences in the inflammatory state of
the two models as neutrophils, the first responders to acute
inflammation, are recruited extensively in rapidly growing ortho-
topic HKP1 tumors, compared with the slower-progressing
spontaneous KP model. In addition, CD4+ T cells were not
significantly increased in HKP1 tumors, whereas an increase in
spontaneous KP tumors was noted. The T cells in early sponta-
neous KP tumors selectively eliminated antigen-expressing tu-
mor cells, resulting in expansion of less-immunogenic tumors
in an advanced stage (DuPage et al., 2011). Possibly, HKP1 cells,
derived from advanced KP tumors, may have lower immuno-
genic potential compared to spontaneous KP tumors. Therefore,
orthotopic tumors derived from HKP1 cells may harbor a dimin-
ished immune response as reflected by lower level of CD4+ cell
recruitment.
The increased prevalence of specific bone-marrow-derived
cells in the TME suggests that these stromal cells may contribute
to NSCLC growth and that further molecular analysis could pro-
vide insights into their reprogrammed state.
Transcriptome Analysis Identified Differentially
Expressed Genes from Individual Stromal and Epithelial
Cell Populations in NSCLC
To determine the reprogrammed/activated state of intratumoral
stromal cells, we focused on the CD11b+ myeloid lineages as
they are significantly elevated and are known to contribute to tu-
mor progression (Hanahan and Coussens, 2012). Moreover,
these populations are amenable to FACS into discrete individual
homogeneous subsets (monocytes, neutrophils, and macro-
phages), owing to distinct cell-surface markers and the availabil-
ity of reliable antibodies (Figure S2E). Importantly, depletion of
specific stromal subsets has been shown to impair tumor growth
in various cancers, indicating their protumorigenic contribution
in cancer (Pyonteck et al., 2013). We restricted our analysis to in-
dividual homogenous cellular compartments isolated directly
from the tumor tissue to unravel cell-specific gene signatures,
which could be missed when using heterogeneous populations
in traditional bulk tumor profiling. Therefore, we did not include
cell types such as fibroblasts, which are heterogeneous, and
lack reliable reagents/methods to yield homogenous popula-
tions (Sugimoto et al., 2006). A schematic of the stromal and1190 Cell Reports 10, 1187–1201, February 24, 2015 ª2015 The Authepithelial cell populations used for transcriptomic analysis by
RNA deep sequencing (RNA-seq) is shown in Figure 2A.
The stromal cell subsets and epithelial cells were sorted
by flow cytometry from lung tissues freshly harvested from
HKP1-tumor-bearing lungs and control WT lungs, using cell-
type-specific surface markers (Figures 2B and S2E). WT resi-
dent macrophages were isolated based on their known surface
markers CD11c+CD11b (Guth et al., 2009). cDNA libraries
were generated and sequenced using Illumina HiSeq2000
sequencers. RNA-seq was performed directly on sorted popu-
lations without subjecting them to in vitro culturing or RNA
amplification to avoid any potential variances in transcript
distribution.
Hierarchical clustering analysis on processed RNA-seq data
showed discrete clustering of individual stromal subsets and
epithelial cells from tumor-bearing and WT lungs (Figure S3).
These results suggest that the RNA-seq data were sufficiently
robust to identify tumor-specific differentially regulated genes
in individual cell populations. We therefore used the LIMMA/
Voom approach (Law et al., 2014; Smyth et al., 2002) to iden-
tify differentially expressed genes in tumor lungs compared to
WT lungs. To visualize differences in gene expression in indi-
vidual cellular subsets isolated from WT lungs and tumor
lungs, we performed principal-component analysis (PCA) us-
ing all genes from each cell population. PCA showed that
the WT and the tumor samples always segregated in two
different areas of the 2D plots in the first dimension (PC1), indi-
cating that the tumor signature is robust (Figure 2C). However,
diversity captured by second dimension (PC2) was observed
within WT samples of monocytes, neutrophils, and epithelial
cells. Gene set enrichment analysis (GSEA) on genes that
contribute to PC2 identified possible pathways that are signif-
icantly associated with the diversity of WT samples, such as
immune response and Golgi transport pathways in neutrophils
and epithelial cell population and cell-proliferation/cell-cycle-
related pathways in monocytes (Table S1). Though the diver-
sity in WT samples from monocytes, neutrophils, and epithelial
cells does correlate with certain pathways, it is apparent that
WT and tumor samples are always clearly separated along
PC1, indicating that WT versus tumor signature dominates
the data.
Next, the most differentially regulated genes in the intratu-
moral stromal subsets and tumor epithelial cells compared to
their WT counterparts were determined using false discovery
rate (FDR) < 5% (Figures 2D and 2E). Among them, we selected
43 genes for additional confirmation in an independent set of WT
and tumor-bearing mice by qRT-PCR. The criteria for selection
included fold changes (>2-fold changes and FDR < 5%) in spe-
cific intratumoral stromal cells and tumor epithelial cells. More
than 80% of analyzed genes showed consistent expression
patterns (fold changes and compartment specificity) between
RNA-seq and qRT-PCR analysis (Figures 3A–3C and S4A–
S4D). Analysis of the cells remaining after sorting the desired in-
dividual populations (Neg) confirmed that the candidate genes
were differentially regulated only in the examined cellular com-
partments in tumor lungs (Figures S4C and S4D). Candidate
genes including Ccl7, Il23a, and Lgr4 were upregulated specif-
ically in macrophages/monocytes, neutrophils, and epithelialors
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Figure 2. Individual Cellular Compartments from Tumor-Bearing Lungs Show Differential Gene Expression Profiles
(A) Schema of RNA-seq analysis of individually isolated populations from WT and HKP1 tumor lungs.
(B) Surface markers that were used for isolation of specific cell populations by FACS.
(C) Principal component analysis (PCA) of RNA-seq data from individual cell populations and total lung cells. Red, tumor samples; blue, WT control samples.
(D) Venn diagram showing upregulated genes from individual myeloid subsets and epithelial cells of tumor lungs compared to WT lungs. The cutoff is FPKM > 5,
fold change > 2, and adjusted p value < 0.05. Epi, epithelial cells; Mac, macrophages; Mon, monocytes; Neu, neutrophils.
(E) Venn diagram showing downregulated genes from individual myeloid subsets and epithelial cells of tumor lungs compared to WT lungs. The cutoff for up-
regulation is FPKM > 5, fold change > 2, and adjusted p value < 0.05. The cutoff for downregulation is FPKM > 5, fold change < 2, and adjusted p value < 0.05.cell compartments, respectively, consistent with RNA-seq data
(Figures 3A–3C). Furthermore, consistent with the RNA-seq
and qRT-PCR data, immunofluorescence staining analysis of
CCL7 and IL23A confirmed CD45+-cell-specific expression of
candidate genes at the protein level (Figures 3D and 3E). Impor-
tantly, analysis of the spontaneous KP model showed that the
candidate genes displayed significant correlation both in expres-
sion levels and compartment specificity (Figures S4E and S4F).Cell RIn the analysis above, we observed that, in a majority of
cases, bulk tissue analysis (total lungs) failed to identify differ-
entially regulated stromal genes (Figures 3A–3C, S4A, and
S4B), highlighting our unique approach of utilizing individual
sorted cell populations from heterogeneous tumor tissues and
demonstrating why many of these genes with stromal-specific
expression patterns had remained undiscovered in previous
whole tumor profiling studies.eports 10, 1187–1201, February 24, 2015 ª2015 The Authors 1191
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Figure 3. Representative RNA-Seq Anal-
ysis, qRT-PCR, and Immunostaining of
Differentially Regulated Genes in Specific
Individual Cellular Compartments
(A) Macrophage- and monocyte-specific differen-
tially regulated genes.
(B) Neutrophil-specific differentially regulated
genes.
(C) Epithelial-cell-specific differentially regulated
genes.
(D) Immunostaining of CCL7 with CD45 and Ep-
cam antibodies in tumor-bearing lung; scale bar
50 mm.
(E) Immunostaining of IL23Awith CD45 and Epcam
antibodies in tumor-bearing lung; scale bar 50 mm.
Epi, Epcam+ CD11bCD11c cells; Mac,
CD11c+CD11b+ cells (tumor), CD11c+CD11b
cells (WT);Mon,CD11b+Ly6C+cells;Mye,mixof all
CD11b+ cells and all CD11c+ cells; Neg, CD11b
CD11c Epcam cells; Neu, CD11b+Ly6G+ cells;
Tot, total lung cells.
Data are shown as mean ± SD.Computational Analysis and Identification of Stroma-
Tumor Paracrine Crosstalk and Tumor Autocrine
Crosstalk in NSCLC
Tumor signaling is mediated by ligand-receptor interactions
within both autocrine and paracrine pathways, which promote
proliferation, survival, and migration in tumor cells (Wyckoff
et al., 2004). Recent studies have begun to identify crosstalk
pathways that have the potential to serve as attractive targets
for anti-cancer therapy (DeNardo et al., 2011; Pyonteck et al.,
2013). However, so far only a limited number of crosstalk path-
ways have been identified in vivo, due to lack of concerted sys-
tematic and global discovery approaches. In this regard, our
multi-cell RNA-seq data generated from tumor-bearing and WT
lungs provides a unique opportunity to identify physiologically
relevant stroma-tumor paracrine and tumor autocrine pathways.
Previous studies have reported network-based analysis for
the identification of signaling networks in biological systems
(Chuang et al., 2007; Komurov, 2012). However, there has
been a lack of reliable computational tools for uncovering cross-
talk pathways between multicellular-stromal components and
tumor epithelial cells. Therefore, we developed a computational
model, CCCExplorer, to uncover stroma-tumor crosstalk-sig-
naling pathways as a directed and connected network from li-
gands-receptor interactions to transcriptional factors (TFs) and
their target genes, as shown in Figure 4. In brief, upregulated li-
gands in tumor-associated stromal cells compared to WT coun-
terparts and their corresponding receptors expressed in tumor
epithelial cells were retrieved as potential crosstalk components.
Activated downstream pathways of the receptors in tumor cells
were identified by analyzing TFs, their upregulated target genes,1192 Cell Reports 10, 1187–1201, February 24, 2015 ª2015 The Authorsand signaling nodes in tumor epithelial
cells. TFs were considered ‘‘activated’’ if
their target genes were upregulated in
the tumor epithelial cells compared to
WT epithelial cells. Thus, signaling path-
ways comprised of upregulated ligands,expressed receptors, and activated downstream TFs were
considered functional. Signaling nodes that connect receptors
and TFs were derived from the signaling pathways information
available in KEGG. In the crosstalk network, each signaling
pathway was denoted by a directed graph, G, including
nodes standing for the genes of ligands, receptors, TFs, and
downstream target genes and edges for the interactions. The
subgraph that was induced collectively by these components
(upregulated ligands, expressed receptors, activated TFs, and
upregulated target genes) was considered as an activated
signaling branch. Each pathway branch deemed significant
(Fisher’s test; p < 0.05) was combined to generate the crosstalk
network. We simplified the combined network by linking recep-
tors directly to the TFs and added the upregulated targets of
the TFs. This model was applied to the RNA-seq data set, and
three paracrine and one autocrine network were generated.
This modeling required comprehensive ligand-receptor net-
work information. The known ligand-receptor information was
obtained from databases including KEGG (Ogata et al., 1999)
and DLRP (Graeber and Eisenberg, 2001). However, these
data sets are incomplete; thus, we derived the subcellular local-
izations of all available proteins in the HPRD database (http://
www.hprd.org) and isolated protein sets with subcellular locali-
zations in ‘‘extracellular’’ and ‘‘secreted’’ to identify additional
ligands to complement the KEGG and DLRP database (Ko-
murov, 2012). Cognate receptors of these ligands were identified
by analyzing protein interactions from the STRING database
(Szklarczyk et al., 2011). The selected ligand-receptor pairs
were evaluated manually to confirm interactions using pub-
lished literature. This allowed us to establish a ligand-receptor
Figure 4. Computational Analysis of Paracrine/Autocrine Crosstalk
Flow chart depicting CCCExplorer model. See also Experimental Procedures.
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interaction database that included 436 ligands, 325 receptors,
and 1,433 ligand-receptor interactions for crosstalk analysis.
We first selected differentially regulated ligands in the intratu-
moral stromal cells and tumor epithelial cells compared to WT
counterparts, using a set of selection criteria based on FPKM >
2, fold change > 1.5, and adjusted p value < 0.1 (Table S2). Simi-
larly, we selected cognate receptors on tumor epithelial cells
with FPKM values > 2 (Table S2). Using these criteria, we identi-
fied upregulated ligands from individual intratumoral cellular
compartments (61 in macrophages, 32 in monocytes, 25 in neu-
trophils, and 62 in tumor cells; Table S2) and 149 genes encoding
receptors expressed in tumor epithelial cells (Table S2). Most of
the ligands passing our threshold have a corresponding adj. p <
0.05. TFs and their target gene information were obtained
from KEGG and TRED (https://cb.utdallas.edu/cgi-bin/TRED/
tred.cgi?process=home). Expressed TFs in tumor cells were
screened using FPKM > 2, and their target genes that were up-
regulated were identified using the same criteria as selecting li-
gands (Table S2). FPKM values of >1 have been widely used to
identify expressed transcripts in RNA-seq analysis (Hart et al.,
2013). The FPKM> 2 threshold in CCCExplorer modeling reliably
identifies TFs, which are known to be expressed at low levels and
are critical in the determination of crosstalk networks. In addition
to these FPKM and fold-change thresholds, additional stringent
parameters in the form of p value cutoffs also enhance signifi-
cance to select differentially expressed genes (adjusted p value <
0.1, from three independent RNA samples) in tumor samples
compared to WT samples and crosstalk-signaling pathways (p
value < 0.05; ligand-receptor-TFs-target genes). Mouse genes
were converted to human orthologous using the mapping pro-
vided by Mouse Genome Informatics database.
From the CCCExplorer analysis, we identified individual stro-
mal-cell-derived, differentially regulated ligands that contribute
to activation of downstream signaling pathways in tumor epithe-
lial cells. Heatmap analysis of those ligands demonstrated
cell-type-specific clustering and upregulated expression in
tumor samples compared to WT samples (Figure 5). FPKM,
fold change, and adj. p values of upregulated ligands from
macrophage-tumor crosstalk network are shown (Figure 5).
Consistently, heatmap of all genes also demonstrated cell-
type-specific gene expression (Figure S5).
CCCExplorer analysis identified pathways that are activated
by paracrine/autocrine crosstalk specifically and included both
previously described and relatively novel signaling pathways in
NSCLC. Tumor-promoting pathways including MAPK, PI3K-
Akt, NF-kappa B, ErbB, Ras, TGF-b, and TNF signaling path-
ways were activated by all of the stroma-tumor paracrine and
tumor autocrine crosstalk (Figures 6, S6, and S7). Importantly,
we identified potentially novel paracrine crosstalk pathways
including IL6-IL6R between macrophages and tumor cells in
NSCLC. In the CCCExplorer analysis, the IL6-IL6R ligand-recep-
tor interaction was predicted to uniquely activate HIF-1 sig-
naling. IL6, a potent activator of STAT3, has been shown to be
secreted by tumor cells in various cancer types (Schafer and
Brugge, 2007). In NSCLC, whereas a tumor autocrine role of
IL6 has been implicated in carcinogenesis (Gao et al., 2007),
the paracrine crosstalk between stromal IL6 and tumor IL6R
has not been reported.1194 Cell Reports 10, 1187–1201, February 24, 2015 ª2015 The AuthSimilarly, the CCCExplorer analysis identified novel paracrine
activation of Wnt-signaling pathway. Macrophages expressed
WNT11 and tumor cells expressed the FZD7 receptor, indicative
of a paracrine crosstalk pathway. Though many studies showed
the tumor-promoting role of autocrine Wnt-signaling pathways
(Anastas and Moon, 2013), paracrine contribution on activation
of Wnt signaling in lung cancer has not been reported.
The macrophage-tumor (Mac-Tum) crosstalk included 22
macrophage-derived differentially regulated ligands and the
presence of 31 cognate receptors on tumor epithelial cells (Fig-
ure 6; Table S3). The interactions between these ligands and
receptors are predicted to induce activation of 39 TFs, leading
to the induction of 14 significant (p < 0.05) signaling pathways
in NSCLC (Figure 6; Table S3). In the Mac-Tum crosstalk anal-
ysis, we identified unique paracrine crosstalks including the
HGF-MET, THBS1-integrin, TNFSF14-LTBR, VEGFA-FLT1, and
WNT11-FZD5/7 between macrophages and tumor epithelial
cells (Figure 6). Importantly, we were able to discern potentially
novel mediators of the activated signaling pathways including
TNFSF14-TNFRSF1A, FN1-integrins, SPP1-integrins, IFNB1-IF-
NAR1/2, IL6-IL6R, and LTB-LTBR in lung cancer (Table S3).
Mac-Tum crosstalk also showed significant induction of the
Wnt-signaling pathway (Wnt11-FZD7 axis), whose role has re-
mained unclear in NSCLC in vivo.
Monocytes-tumor (Mon-Tum) crosstalk included 11 mono-
cyte-derived ligands and 16 cognate receptors on tumor cells.
These ligand-receptor pairs are predicted to induce ten signaling
pathways (p < 0.05) through 31 TFs (Figure S6A; Table S4).
Whereas many of these pathways were also observed in the
Mac-Tum analysis above, specific crosstalk pathways including
the AREG-EGFR signaling were also identified. The AREG-EGFR
axis activates ErbB signaling (Table S4) and has been reported in
diverse cancer types including breast, colorectal, brain, and liver
(Katoh and Katoh, 2006). In lung cancer cells, elevated levels of
AREG has been shown to inhibit apoptosis (Hurbin et al., 2002)
and leads to resistance to the EGFR inhibitor gefitinib (Busser
et al., 2010). Therefore, in our analysis, the identification of the
AREG-EGFR axis in vivo suggests a potential tumor-promoting
role in NSCLC.
Neutrophil-tumor (Neu-Tum) crosstalk included eight neutro-
phil-derived ligands and 17 cognate receptors on tumor epithe-
lial cells. The interactions between these ligands and receptors
are predicted to induce 33 TFs, leading to the activation of 11
significant (p < 0.05) signaling pathways in NSCLC (Figure S6B;
Table S4). Distinctively, Neu-Tum crosstalk revealed the TGFB1-
TGFBRII interaction, which was not observed in other stroma-tu-
mor crosstalk (Figure S6B). The dual role of TGF-b1 in cancer
is reported in many cancer cells. The anti-proliferative and
apoptotic tumor-suppressive activity of the TGF-b1-TGF-b
type II receptor interaction is compromised in many cancer cells.
In addition to compromised tumor-suppressive signaling arm,
TGF-b promotes tumor growth, invasion, and metastasis.
Further, TGF-b contributes to tumor growth by suppressing
anti-tumor immune and inflammatory response (Massague´,
2008). In lung cancer, elevation of TGF-b1 has been observed
in tumor and blood of lung cancer patients (Barthelemy-Brichant
et al., 2002; Kim et al., 1999). Furthermore, expression of TGF-b
type II receptor is commonly observed to be reduced in lungors
Figure 5. Heatmap Depicting Differentially Regulated Ligands across Cell Populations Derived from Lungs from WT and HKP1-Tumor-
Bearing Mice
Heatmap was generated using gplots R package (Warnes et al., 2014) from selected upregulated ligands (FPKM > 2, fold change > 1.5, and adj. p < 0.1) of each
cell type. The enriched functions (GO terms) of specifically upregulated genes were analyzed using DAVID (http://david.abcc.ncifcrf.gov/). A table shows FPKM
and fold change of the ligands from macrophage-tumor crosstalk network.cancer epithelial cells (Anumanthan et al., 2005; Kim et al., 1999).
However, the function of TGF-b in lung cancer progression is
controversial. Dysregulation of TGF-b signaling was identified
as an important mediator of lung cancer invasion (Toonkel
et al., 2010). In contrast, TGFBRII siRNA treatment suppressed
tumor cell proliferation and invasion and increased apoptosis
of the A549 lung cancer cell line in vitro (Xu et al., 2011) andCell RTGF-b1 promotes lung cancer growth indirectly by polarization
of macrophages via IRAK-M (Standiford et al., 2011).
In the HKP1 lung cancermodel, TGF-b type II receptor expres-
sion is not significantly reduced (adj. p > 0.05) in tumor cells.
Thus, extensive mutation analysis on TGF-b type II receptor
and cytostatic genes including p15INK4b and c-MYC may pro-
vide important insights into the contribution of TGF-b-signalingeports 10, 1187–1201, February 24, 2015 ª2015 The Authors 1195
Wnt
Hippo, Wnt
Hippo, TGF-β
TGF-β
MAPK, PI3K-Akt,
NF-kB,
Osteoclst diff.
TNF
MAPK, 
PI3K-Akt
ErbB, Focal ad.,  
MAPK, TNF, Wnt
Osteoclast diff. 
MAPK, NF-kB, 
PI3K-Akt, 
Osteoclast diff.,
TNF
TGF-β, HIF-1
PI3K-Akt
ErbB, GnRH
Ostoeclast, diff., MAPK, NF-kappaB
Focal ad., Rap1, PI3K-Akt, Ras
NF-kB
Hippo
TGF-β
Focal ad., 
PI3K-Akt MAPK, TNF, 
Rap1, Osteoclast diff.
Osteoclast diff., PI3K-Akt
HIF-1, PI3K-Akt
TNF
NF-kB, MAPK, 
Osteoclast diff.
PI3K-Akt, Rap1, Ras
TGF-β
Hippo
MAPK
ErbBErbB
HIF-1
HIF-1, TGF-β
ErbB, Focal ad., 
GnRH, MPAK, 
Ras
MAPK, 
Osteoclast  diff. HIF-1
Focal ad., PI3K-Akt, Rap1, Ras
Focal ad., Rap1, 
PI3K-Akt, Ras
ErbB, Hippo, 
MAPK, PI3k-Akt,
TGF-β, Wnt
PI3K-Akt
ErbB, Focal ad.,
GnRH, PI3K-Akt, Ras
HIF-1
Osteoclast diff.
Tumor cellExtracellular space
Hippo
Focal ad., 
PI3K-Akt
Focal ad., 
PI3K-Akt
Hippo, Wnt
Osteoclast diff., PI3K-Akt
Hippo, Wnt
NF-kappaB
Hippo, TGF-β
Hippo, TGF-β
Osteoclast
diff.
Hippo, 
TGF-β
Osteoclast
diff.
Hippo
Hippo
Hippo
Ligand
Receptor
TF
Target gene
Cell membrane
MAPK signaling
(p=1.78E-07)
PI3K-Akt signaling
(p=7.43E-07)
Hippo signaling
(p= 1.82E-06)
TGF-beta signaling
(p=2.67E-06)
NF-kappa B signaling
(p=0.009329)
Focal adhesion
(p=0.0010242)
GnRH signaling
(p=0.014243)
Rap1 signaling
(p=0.024963)
Osteoclast differentiation
(p=4.42E-06)
TNF signaling
(p=3.22E-05)
HIF-1 signaling
(p=0.000291)
ErbB signaling
(p=0.001745)
Wnt signaling
(p=0.025756)
Ras signaling
(p=0.035806)
Ligand-Receptor interaction
Receptor-receptor interaction 
(heterodimers)
Receptor-TF interaction
TF-target gene interaction
Figure 6. Paracrine Crosstalk Network between Macrophages and Tumor Cells
Macrophage-derived ligands in extracellular space, cognate receptors, transcription factors, and downstream target genes in the tumor cells generate networks
of activated signal transduction pathways. The signaling pathways that are significantly activated by these interactions (p < 0.05 by Fisher test) are depicted in a
box (see also Table S4).pathway in NSCLC, as observed in subsets of breast cancer (Go-
mis et al., 2006).
In addition to stroma-tumor paracrine crosstalk analysis, we
evaluated tumorautocrinecrosstalk signaling. This included22 tu-
mor-derived ligands and 29cognate receptors on tumor cells. The
interactions between these ligands and receptors are predicted to
induce33TFs, leading to theactivationof12 tumor-signalingpath-
ways (Figure S7; Table S5). The CCCExplorer analysis identified
unique crosstalks in tumor autocrine signaling of lung cancer,
such as BTC-EGFR, EFNA5-EPHA2, EREG-EGFR, WNT10A-
FZD5/7, WNT4-FZD5/7, and WNT5A-FZD1/2/5/7. In addition,
distinct upregulation of diverse extracellular matrix (ECM) compo-
nents such as fibronectin, tenascin C, collagens, and laminin var-
iants has the potential to regulate tumor cell behavior through their
unique physical, biochemical, and biomechanical properties in
lung cancer. Furthermore, ECM interactions with receptors on tu-
mor cells induce signal transduction in tumor cells (Kessenbrock
et al., 2010). Previous studies have shown that interaction of1196 Cell Reports 10, 1187–1201, February 24, 2015 ª2015 The AuthECM proteins and b1-integrin protects cancer cells against
apoptosis in small cell lung cancer (Sethi et al., 1999). Although
little is known in NSCLC, our analysis suggests that the ECM-in-
tegrin interactions may contribute to focal adhesion and PI3K-
Akt-signaling pathway activation in NSCLC (Table S5).
Individual myeloid cells displayed common ligand-receptor in-
teractions, involving IL1A, TNF, INHBA, andHB-EGF, suggesting
that cells were reprogrammed in a similar way in the TME.
Whereas paracrine crosstalk pathways between individual
stromal cells and tumor epithelial cells revealed similarities with
many common ligand-receptor interactions, tumor autocrine
crosstalk pathways displayed unique pathways mediated by
BTC-EGFR, EREG-EGFR, collagen-integrins, TNC-integrins,
and laminins-integrins, diverse WNT ligands (WNT4, WNT5A,
and WNT10A).
Interestingly, irrespective of the cell type, we also observed
global ligand-receptor interactions including the INHBA-
ACVR2A axis, indicating that multiple cell populations areors
involved in activation of a single pathway. Increased INHBA ex-
pression has been shown to promote tumor cell proliferation in
lung adenocarcinoma (Seder et al., 2009), and its upregulation
is associated with poor outcome in lung adenocarcinoma and
gastric cancer (Seder et al., 2009); however, its role in lung can-
cer is not fully understood. The complexity of the TME was also
observed in the form of expression of multiple variants of ligands
and receptors. For example, we observed multiple variant WNT
ligands from macrophages (WNT11) and tumor cells (WNT4,
WNT5A, and WNT10) and multiple FZD receptor (FZD5, FZD7,
and FZD8) expression on tumor cells, indicating combinatorial
ligand-receptor interactions and a diverse level of Wnt or Hippo
signaling pathway regulation.
Identification of activated downstream signaling pathways
suggested that the identified ligand-receptor crosstalk has
the potential to trigger physiological and functional changes via
signal transduction pathways in tumor cells. Importantly, a
number of ligand-receptor interactions (both paracrine and
autocrine) that do not have annotated downstream signaling
pathways were also identified (Tables S3, S4, and S5).
Future studies will be necessary not only to determine their
roles in carcinogenesis but also to evaluate their potential
as novel diagnostic, prognostic, or therapeutic targets for lung
cancer.
Experimental Validation of CCCExplorer-Predicted
IL6-IL6R Paracrine Crosstalk Pathway between
Macrophages and Tumor Epithelial Cells
Among the potential crosstalk pathways predicted by the
CCCExplorer analysis, we selected the IL6-IL6R macrophage-
tumor paracrine crosstalk pathway for experimental validation.
In HKP1 tumors, IL6 expression was specifically increased in
themacrophages andmonocytes compared toWT counterparts
(Figure 7A). Noticeably, the IL6 receptor was expressed in HKP1
tumor epithelial cells (Figure 7B). Previous studies have shown
that IL6 is a potent activator of the JAK/STAT3 pathway (Zhong
et al., 1994), and both autocrine and paracrine IL6/STAT3
signaling has been shown to promote breast cancer progression
(Chang et al., 2013). We chose the IL6-IL6R-STAT3 paracrine
pathway because, in lung cancer, the autocrine role of IL6 in
inducing STAT3 has been demonstrated (Gao et al., 2007); how-
ever, the paracrine crosstalk between stromal IL6 and tumor
IL6R has not been reported. Therefore, to test the paracrine-
signaling pathway, we established an in vitro system comprised
of macrophages and HKP1 tumor cells. Macrophages were
differentiated from freshly harvested murine bone marrow cells
as described (Weischenfeldt and Porse, 2008), with an efficiency
of >90% as determined by expression of CD11b, CD68, and F4/
80 (Figure 7C).
To emulate the paracrine interaction in the TME in vitro, we
used an experimental approach depicted in Figure 7D. Using
this approach, we observed that HKP1 tumor-conditioned
media (T-CM), which did not contain IL6, was able to stimulate
IL6 production in WT macrophages, but not in Il6/ macro-
phages, as determined in MacT-CM (Figure 7E). Strikingly,
MacT-CM activated STAT3 significantly (>10-fold, compared
to Mac-CM) in HKP1 tumor cells as determined by elevated
phospho-STAT3 levels (Figure 7F). Notably, MacT-CM derivedCell Rfrom Il6/ macrophages failed to activate p-STAT3 signifi-
cantly, suggesting that IL6 in the macrophage supernatant
mainly contributes to STAT3 activation in tumor cells. Next,
we determined the paracrine role of IL6 in conferring protumori-
genic properties on tumor cells. Treatment of HKP1 cells with
recombinant IL6 increased migration and impaired apoptosis,
indicative of a tumor-promoting function of IL6-IL6R interaction
(Figures 7G and 7H).
Together, these findings not only validate the IL6-IL6R-STAT3
paracrine crosstalk pathway predicted by the CCCExplorer anal-
ysis but also suggest the therapeutic potential of targeting this
pathway in NSCLC.
DISCUSSION
In previous studies, a limited number of tumor-stroma crosstalk
pathways have been identified. Importantly, these pathways
have been shown to contribute significantly to carcinogenesis,
warranting a more systematic genome-wide analysis to unravel
additional pathways. In this context, genomic analysis of limited
stromal cells in breast cancer identified cell-specific targets
(Allinen et al., 2004). However, in this study, comprehensive
crosstalk pathways analysis was not performed. Other studies
have relied on in vitro co-culture analysis, and the in vivo utility
of the identified pathways has been limited.
Here, a systematic analysis of individual stromal and epithe-
lial compartments in NSCLC, together with a predictive
modeling, has revealed known and relatively novel key tu-
mor-stromal paracrine and tumor autocrine crosstalk path-
ways in the lung cancer microenvironment, with information
of specific producers of ligands. The experimental design
employed in this study is innovative and is the first to use
genome-wide RNA-seq analysis of purified individual stromal
and epithelial cell compartments directly from freshly procured
tissues. The design allowed quantitative analysis of differen-
tially regulated genes in specific cell populations of interest,
particularly stromal cells, which are often missed in traditional
whole bulk tumor tissue profiling. Another unique feature is
the development of the CCCExplorer model to computation-
ally integrate multicellular transcriptome- and interactome-
signaling data and to incorporate existing ligand-receptor
interactions to discover and score the inter-cellular crosstalk-
signaling pathways.
Whereas we have identified potential crosstalk pathways
in NSCLC, a reasonably complete, graphic depiction of the
network of microenvironmental signaling interactions is still far
beyond our reach, as many signaling molecules and pathways
remain unclear. Furthermore, the computational analysis of
paracrine and autocrine pathways relied solely on transcriptome
profiles of individual cellular stromal subsets and tumor epithelial
cells from NSCLC. Whereas the transcriptomic profiles provided
quantitative changes in gene expression levels of ligands, recep-
tors, and components of the downstream signaling pathways
such as TFs and their target genes, limitations associated with
the absence of protein data impose significant challenges in
the identification of many activated pathways. Thus, future
studies should incorporate analysis of phosphorylated proteins,
which are more-robust indicators of downstream signaling.eports 10, 1187–1201, February 24, 2015 ª2015 The Authors 1197
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Figure 7. Experimental Validation of IL6-
IL6R Paracrine Crosstalk between Macro-
phages and Tumor Epithelial Cells
(A) RNA-seq and qRT-PCR analysis of Il6 expres-
sion from individually isolated populations from
WT and HKP1 tumor lungs. Data are shown as
mean ± SD.
(B) RNA-seq analysis of IL6 receptor genes in tu-
mor epithelial cells. Data are shown as mean ± SD.
(C) Flow cytometry analysis of macrophages
differentiated from bone marrow cells, using cell
surface markers CD11b, Gr1, CD68, and F4/80.
The parental cell population for each analysis is
indicated on the top of each plot.
(D) Schema depicting treatment of macrophages
with media alone or tumor-conditioned medium
(T-CM) to generate macrophage-conditioned me-
dium, Mac-CM and MacT-CM, respectively.
(E) ELISA of IL6 from WT or Il6/ macrophage
CM generated by the schema described in (D).
Each sample was pooled from more than three
wells.
(F) Western blot of p-STAT3 and STAT3 in HKP1
tumor cells following treatment with conditioned
media (Mac-CM and MacT-CM) from WT macro-
phages and Il6/ macrophages. Bands were
quantitated, and values are presented below each
blot.
(G) HKP1 cell wound healing assay with IL6 treat-
ment (n = 3). Data are shown as mean ± SEM. *p <
0.05 by Mann-Whitney U test.
(H) Apoptosis assay with annexin V in HKP1 tumor
cells following recombinant IL6 treatment (n = 3).
Data are shown as mean ± SEM. *p < 0.05 by
Mann-Whitney U test.Despite these limitations, our approach has identified known and
novel paracrine crosstalk pathways between individual myeloid
and tumor cells and tumor cell autocrine pathways. The experi-
mental validation of IL6-IL6R paracrine crosstalk pathway be-
tween macrophages and tumor cells confirmed that other para-
crine crosstalk pathways discovered by CCCExplorer analysis
may have also functional significance. Therefore, rapid experi-
mental validation of the CCCExplorer-predicted crosstalk path-
ways constitutes an essential next step to consider mechanistic
explorations in vivo. Exploring the mechanistic basis of these
pathways is likely to confer insights into the biology of the dis-1198 Cell Reports 10, 1187–1201, February 24, 2015 ª2015 The Authorsease and may lead to the development
of potential novel stromal therapeutic tar-
gets against NSCLC, particularly Kras-
driven adenocarcinoma, either alone or
in combination with conventional treat-
ments that target cancer cells.
EXPERIMENTAL PROCEDURES
For further details, please see the Supplemental
Experimental Procedures.
All animal work was conducted in accordance
with a protocol approved by the Institutional
Animal Care and Use Committee. Human lung
adenocarcinoma was obtained from New YorkPresbyterian Hospital/Weill Cornell Medical College in accordance with a
protocol approved by the IRB.
RNA-Seq Analyses
RNA-seq reads were analyzed using FastQC to detect potential problems.
Then, short reads were aligned to the mm9 reference genome using TopHat
with default parameters. FPKMs (fragments per kilobase per million map-
ped reads) (Mortazavi et al., 2008) were determined for all RefSeq genes
using CuffLinks. Read counts were obtained using HTseq (Anders et al.,
2014).
Differential expression analysis was performed using the LIMMA/Voom
approach. We used PCA to determine how individual samples relate to each
other based on all gene expression profiles. Differentially regulated geneswere
further analyzed for overlap and visualized using Venny (Oliveros, 2007).
Development of the CCCExplorer Model
The workflow for modeling and discovering multi-crosstalk in CCCExplorer is
given below.
Algorithms to find activated pathway branches:
Find all upregulated ligands in stromal cells, denoted by L, and all expressed
receptors in tumor cells, denoted by R. All LR interactions with ligands in L and
receptors in R are selected as potential crosstalks between stromal and tumor
cells.
Find all upregulated genes in tumor cells, denoted by Tup. For each TF, let
LTF denote its targets list. Let Lall denote all annotated gene lists in the data-
matched human orthologous. Fisher test is applied where a=
Tup X LTF ,
b=
Tup a, c= jLTF j  a, d = jLall j  ða+b+ cÞ and probability P is calculated
by
P=

a+b
a

c+d
c


a+b+ c+d
a+ c


n
k

is the binomial coefficient. Then, the p value is calculated using stats R
package. Thosewith p < 0.05 are considered as activated TFs, denoted by TTF.
For each KEGG pathway, remove the ligands that are not in L and receptors
that are not inR. For all other genes, create a directed networkG(V,E), where V
stands for the gene sets in the pathway and E stands for the interactions be-
tween them. Calculate the distance matrix D=(dij), where dij is the distance
from Vi to Vj, i.e., the length of shortest pathway from Vi to Vj. For Vi˛L, find
all nodes that are reachable from Vi, denoted by NVi , where dij < Inf for every
Vj˛NVi . Let NL =
P
Vi˛LNVi . For Vk˛TTF , find all nodes that can reach Vk, de-
noted by NVk , where dlk < Inf for every Vl˛NVk . Let NTF =
P
Vk˛TTF NVk . Finally,
the subgraph induced by Vlink =NLXNTF is considered as activated pathway
branch, denoted by H=G[Vlink].
The significance of downstream genes in each activated signaling branch H
was evaluated using Fisher test similar to the one used by testing TFs. All li-
gands and receptors were excluded because we only focused on the down-
stream signaling of receptors. Activated TFs were considered upregulated
regardless of their expression values in tumor cells. Those pathway branches
with p<0.05were selected as significant activated pathway branches, denoted
by Hsig. We then revised Hsig by linking the ligands directly to the activated TFs
and adding in the activated target genes of these TFs. The cell communication
network between each stromal and tumor cells is then the combination of Hsig,
i.e.,
S
Hsig.
The codes are available at http://209.160.41.231/u54/CCCExplorer/.
Paracrine/Autocrine Crosstalk Computational Analysis
For CCCExplorer analysis, RNA-seq reads were analyzed using the computa-
tional pipeline from the S.T.C.W. lab at Houston Methodist hospital for cross-
talk analysis. Briefly, fragment reads were mapped to UCSC mouse genome
(mm10/GRCm38) using Tophat2. Raw counts for each gene were obtained
by Cufflinks and then converted to FPKMs and scaled via the median of the
genomic means for each gene across all libraries as described (Anders and
Huber, 2010). Adjusted p values for each gene were obtained by cuffdiff 2.
Activated pathway branches were found using the CCCExplorer model on
RNA-seq data from isolated myeloid and epithelial cells. The significance of
each pathway branch that was activated in the crosstalk was evaluated using
the Fisher test.
In Vitro Macrophage Differentiation Experiment
To obtain macrophages, total bonemarrowwas harvested from C57BL/6JWT
mouse (Jax 00064) and Il6/ mouse (Jax 2650) and cultured for 7 days in
DMEM supplemented with 10% FBS, L-glutamine, penicillin/streptomycin,
and 20% of L929 cell-conditioned media enriched for CSF1 for macrophage
differentiation. L929 cell-conditioned media was prepared from confluent
L929 in DMEM-supplemented 10% FBS, L-glutamine, and penicillin/strepto-
mycin. To collect macrophage-conditioned media for tumor cell treatment, 1Cell Rmillion macrophages were seeded in a well of 6-well plates and treated either
with serum-free HKP-1 T-CM or with serum-free DMEM and then incubated
overnight. Cell debris was removed by centrifugation, and the collected super-
natants were labeled as Mac-CM (DMEM treated) or MacT-CM (HKP1 T-CM
treated). IL6 was measured by ELISA (R&D Systems) according to manufac-
turer’s manual.
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